Synergism between resveratrol and other phytochemicals: Implications for obesity and osteoporosis

Abstract

Resveratrol, a phytoalexin, has gained much attention recently due to its effects on sirtuins. While the anti-cancer properties of resveratrol have been extensively investigated, the anti-adipogenic and osteogenic effects of resveratrol are also gaining considerable interest. The finding that resveratrol supplementation mimics caloric restriction prompted researchers to study the effects of resveratrol on lipid metabolism. Mesenchymal stem cells are the precursors for both adipocytes and osteoblasts. In the aging population, differentiation to adipocytes dominates over the differentiation to osteoblasts in bone marrow, contributing to the increased tendency for fractures to occur in the elderly. Thus, an inverse relationship exists between adipocytes and osteoblasts in the bone marrow. Resveratrol acts on several molecular targets in adipocytes and osteoblasts leading to a decrease in adipocyte number and size and an increase in osteogenesis. Furthermore, resveratrol in combination with genistein and quercetin synergistically decreased adipogenesis in murine and human adipocytes. A recent in vivo study showed that phytochemicals including resveratrol in combination with vitamin D prevented weight gain and bone loss in a postmenopausal rat model. Therefore, combinations of resveratrol with other phytochemicals may lead to potential novel potent therapies for both obesity and osteoporosis.

Potensi Suplementasi Resveratrol dalam Mengatasi Efek Negatif Hormon Tiroid pada Terapi Obesitas: Uji Preklinik

“…Sebanyak 50 nukleoid dari masing-masing sampel dianalisis mempergunakan software TriTek Comet Score Freeware 1.6.1. 13. Kerusakan DNA dinilai dengan parameter tail moment, yaitu hasil perkalian tail length dengan tail DNA %.…”

“…12 Lebih lanjut, RSV menurunkan jumlah adiposit dengan cara menurunkan adipogenesis serta mampu menginduksi apoptosis melalui peningkatan aktivitas SIRT-1 yang menekan ekspresi dari peroxisome proliferator-activated receptor (PPAR)-γ dan juga menginhibisi jalur (PI3K)/Akt sehingga meningkatkan ekspresi gen Bac/Bcl-2. 5,13 Hasil ini memperlihatkan hal positif dari penambahan RSV karena tujuan utama pengobatan obesitas adalah menurunkan massa lemak, bukan menurunkan massa otot.…”

Computational pharmacokinetics and in vitro-in vivo correlation of anti-diabetic synergistic phyto-composite blend

“…Akt phosphorylation also targets FOXO mediated transcription of target genes that promote the production of β-cells. To coun- synergism [11,12] . Synergy can give better outcomes in terms of pharmacokinetic profile or physicochemical effects based on enhanced solubility profile, improved absorption and ultimately better bioavailability.…”

“…While synthesizing or processing a single entity, unwanted adverse effects may develop due to either the extraction procedure or synthetic scheme being followed, or development of any by products; such adverse effects can be minimized or eliminated by use of combo formulations. Moreover stability issues of one to several bio-actives on long storage are more protected in combined form than in isolated form [11,12] . Combination therapy has made its way in the treatment of type 2 diabetes whether it is western classical medicine or herbal formulations.…”

“…Medicine in recent times, whether western classical or phyto-therapy, advocates for combination therapy, instead of single approach. Synergy research in phytotherapy, with the aid of "omics technologies" needs a rationale for establishing its pharmacological and therapeutic superiority to treat diseases which have hitherto been treated using synthetic drugs alone [11][12][13][14][15] . Along with the paradigm of translational health research with the perspectives of bench to bedside approach; all pharmaceutical RDs target to develop robust, cost effective, enhanced throughput in vitro assays which may be extrapolated to humans and serve the purpose of bio-waiver.…”